Analysis of COVID-19 Cases and Public Measures in China
- PDF / 617,131 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 52 Downloads / 193 Views
COVID-19
Analysis of COVID-19 Cases and Public Measures in China Chun-Song Hu 1 Accepted: 21 July 2020 # Springer Nature Switzerland AG 2020
Abstract This paper briefly analyzes COVID-19 cases during Wuhan lockdown and travel restrictions on 23 January 2020 to 23 June 2020, which included total confirmed, in critical condition, deaths, recovered, and suspected cases in China. Results showed that there were 28,942 suspected cases on February 8, 2020, at the peak; then, it almost declined continually to only several cases. Total confirmed cases were more than 80,000 on March 1, 2020, but less than 84,000, and deaths were more than 3000 on March 4, 2020, but less than 4640, totally, thanks for the right public measures for COVID-19 in China, such as the Wuhan City lockdown and travel restrictions for isolation; positive screening and testing; and establishing a Huoshenshan hospital, a Leishenshan hospital, and a number of Fangcang shelter hospitals, traditional Chinese medicine and a combination of Chinese and western medicine, and the launch of the clinical trials of antiviral drugs (Lianhua Qingwen, remdesivir, and chloroquine). In addition, the iRT-ABCDEF program is very useful to control domestic, imported, and asymptomatic cases. Cases in critical condition decrease continually after the peak of 11,977 cases on February 18, 2020, and recovered cases increase continually to over 78,400 cases due to these right public measures and effective treatments. In recent months, there are only 2 deaths and only about ten cases in critical condition. All in all, these public measures in China are confirmed to be very effective and are worth conducting in countries worldwide. Keywords COVID-19 . Infectious disease . Prevention . Public heath . SARS-CoV-2
Introduction The outbreak of a severe respiratory disease [1, 2] at the end of 2019 has already been controlled successfully in China. This emerging infectious disease was ever named a novel coronavirus (2019-nCoV) pneumonia (NCP), and it is a major threat to public health according to the World Health Organization (WHO). Then, this coronavirus SARS-CoV-2 disease was named as COVID-19 by the WHO. Genome sequences from samples of patients confirmed that a novel RNA virus originated from its natural reservoir host—bats [3, 4]. But an animal just represents an intermediate host [5]. And pangolins should also be considered as possible hosts since metagenomic sequencing identified pangolin-associated coronaviruses [6]. The angiotensin-converting enzyme 2 (ACE2) is a possible entry This article is part of the Topical Collection on Covid-19 * Chun-Song Hu [email protected] 1
Department of Cardiovascular Medicine, Nanchang University, Hospital of Nanchang University, Jiangxi Academy of Medical Science, No. 461 Bayi Ave, Nanchang 330006, Jiangxi, China
receptor for SARS-CoV-2 binding cell in humans. Here is a preliminary analysis of COVID-19 cases during Wuhan lockdown and travel restrictions on 23 January 2020 to 23 June 2020, which included total confirmed, in critical condition,
Data Loading...
